13.380
+0.060
+(0.45%)
At close: 4:08:01 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
14,009,159
13,739,879
11,334,262
9,703,438
8,772,488
Cost of Revenue
7,543,255
7,405,042
6,365,272
5,492,391
4,966,270
Gross Profit
6,465,904
6,334,837
4,968,990
4,211,047
3,806,218
Operating Expense
2,790,350
3,045,518
2,877,596
2,744,047
2,490,112
Operating Income
3,675,554
3,289,319
2,091,394
1,467,000
1,316,106
Net Non Operating Interest Income Expense
58,250
38,519
-10,858
22,549
-68,485
Pretax Income
3,633,695
3,344,148
2,006,766
1,202,647
882,334
Tax Provision
726,095
643,303
425,743
213,062
181,416
Net Income Common Stockholders
2,908,258
2,701,350
1,581,094
988,098
702,989
Diluted NI Available to Com Stockholders
2,908,258
2,701,350
1,581,094
988,098
702,989
Basic EPS
1.60
1.49
0.87
0.54
0.40
Diluted EPS
1.60
1.49
0.87
0.54
0.40
Basic Average Shares
1,817,027
1,817,027
1,819,730
1,840,043
1,765,968
Diluted Average Shares
1,817,027
1,817,027
1,819,730
1,840,043
1,765,968
Total Expenses
10,333,605
10,450,560
9,242,868
8,236,438
7,456,382
Net Income from Continuing & Discontinued Operation
2,908,258
2,701,350
1,581,094
988,098
702,989
Normalized Income
2,917,750.502
2,692,634.022
1,595,349.289
1,245,603.034
977,286.578
Interest Income
111,582
105,415
70,737
82,780
112,788
Interest Expense
53,332
66,896
81,595
60,231
181,273
Net Interest Income
58,250
38,519
-10,858
22,549
-68,485
EBIT
3,687,027
3,411,044
2,088,361
1,262,878
1,063,607
EBITDA
4,254,845
3,976,692
2,640,792
1,883,735
1,678,072
Reconciled Cost of Revenue
7,543,255
7,405,042
6,365,272
5,492,391
4,966,270
Reconciled Depreciation
567,818
565,648
552,431
620,857
614,465
Net Income from Continuing Operation Net Minority Interest
2,908,258
2,701,350
1,581,094
988,098
702,989
Total Unusual Items Excluding Goodwill
-11,863
10,792
-18,094
-312,947
-345,293
Total Unusual Items
-11,863
10,792
-18,094
-312,947
-345,293
Normalized EBITDA
4,266,708
3,965,900
2,658,886
2,196,682
2,023,365
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-2,370.498
2,076.022
-3,838.711
-55,441.966
-70,995.422
12/31/2020 - 6/15/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
1681.HK CONSUN PHARMA
9.630
-1.33%
3692.HK Hansoh Pharmaceutical Group Company Limited
22.150
-2.85%
CSWYY China Shineway Pharmaceutical Group Limited
18.53
0.00%
IPSEF Ipsen S.A.
103.50
0.00%
2005.HK SSY Group Limited
3.020
-1.31%
0512.HK GRAND PHARMA
5.600
-3.45%
2877.HK China Shineway Pharmaceutical Group Limited
7.740
-0.26%
3320.HK China Resources Pharmaceutical Group Limited
4.960
-1.20%
2633.HK Jacobson Pharma Corporation Limited
1.250
-1.57%
1558.HK HEC CJ PHARM
11.500
0.00%